During a live broadcast of CURE Connections, held during the Seventh Annual Ruesch Center Symposium: Fighting a Smarter War on Cancer on Dec. 3 in Washington, D.C., a panel that included an oncologist, a nurse, an oncology dietitian and a patient advocate discussed the importance of nutrition when trying to manage a long list of symptoms.
More than 11 years ago, a report from the Institute of Medicine recommended that every cancer survivor should have a comprehensive care summary and follow-up plan, or a survivorship care plan. However, a recent survey found that more than half of the 500 gastrointestinal cancer patient participants didn’t know what a survivorship care plan was.
Metastatic colorectal cancer (mCRC) has been transformed from a one-drug disease with a median overall survival (mOS) rate of 6 months to one that presents an opportunity for multiagent, multimodality treatment pathways with an overall survival (OS) rate of nearly 3 years.
Practitioners received insight into treating patients across the GI field—colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, neuroendocrine tumors (NETs), gastric cancer, and sarcomas—during the GI cancers track at the 2016 Chemotherapy Foundation Symposium.
Two major developments in oncology—the dramatic success of some immunotherapies and targeted drugs and an equally dramatic rise in the cost of care—have created policy issues, more serious than ever, regarding access to care.
Progress has been too slow for patients with gastrointestinal cancers,” says Craig Lustig, associate director of the Ruesch Center for the Cure of GI Cancers. Part of Georgetown Lombardi Comprehensive Cancer Center, the Ruesch Center became founding member and academic center for the new GI Cancers Alliance.
The unprecedented understanding of cancer as a series of complex diseases holds the promise of new, more effective therapies for GI cancer patients, and indeed all cancer patients. The briefing examined the rapid advances in science around cancer, increasing costs and clinical value of new discoveries and creating a balance that ensures patient access.